Clinical Trials Logo

Alzheimer Disease clinical trials

View clinical trials related to Alzheimer Disease.

Filter by:

NCT ID: NCT03770182 Recruiting - Alzheimer Disease Clinical Trials

Brain Stimulation for Neurological Patients

Start date: January 24, 2017
Phase: N/A
Study type: Interventional

This is a prospective double-blind randomized placebo-controlled crossover clinical trial

NCT ID: NCT03765762 Recruiting - Alzheimer Disease Clinical Trials

A Study to Assess the Safety of GRF6019 Infusions in Subjects With Severe Alzheimer's Disease

Start date: December 2018
Phase: Phase 2
Study type: Interventional

This study will evaluate the safety, tolerability, and potential cognitive benefit of the experimental treatment GRF6019 in subjects with severe Alzheimer's disease.

NCT ID: NCT03761381 Recruiting - Alzheimer Disease Clinical Trials

OCT Angiography and NRAI in Dementia

Start date: September 14, 2018
Phase:
Study type: Observational

The primary goals of this study are to use optical coherence tomography (OCT) angiography (blood vessel mapping) to: 1. Detect retinal blood vessel and blood flow changes in participants with dementia. 2. Detect amyloid protein deposits in the retinas of participants with dementia.

NCT ID: NCT03757910 Not yet recruiting - Alzheimer Disease Clinical Trials

Brain Imaging in the Diabetes Prevention Program Outcomes Study

DPPOS-Brain
Start date: January 2019
Phase: Early Phase 1
Study type: Interventional

This is a cross-sectional pilot study of Alzheimer's disease (AD) brain imaging biomarkers in Diabetes Prevention Program (DPP) outcomes study (DPPOS) participants from the New York City sites (Columbia and Einstein), comparing 10 persons originally randomized to metformin and 10 persons randomized to placebo in DPP. All study procedures will be conducted at Columbia University Irving Medical Center. Eligible participants will receive a PET scans and a brain MRI, which may be conducted in one, two, or three separate visits.

NCT ID: NCT03757325 Recruiting - Alzheimer Disease Clinical Trials

Study to Evaluate DNL747 in Subjects With Alzheimer's Disease

Start date: December 2018
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple oral doses of DNL747 in subjects with Alzheimer's disease when administered for 29 days in a cross-over design

NCT ID: NCT03752463 Recruiting - Alzheimer Disease Clinical Trials

NMDA Enhancer for the Treatment of Mild Alzheimer's Disease

Start date: May 22, 2015
Phase: Phase 2
Study type: Interventional

NMDA neurotransmission plays an important role in learning and memory. NMDA receptors (NMDAR) were found to decrease in the frontal lobe and hippocampus of Alzheimer's disease (AD). This study is a randomized, double-blind, placebo controlled drug trial for testing the efficacy of NMDAR-enhancer. All subjects will be allocated randomly to 4 groups: (1) DAOI-A group; (2) DAOI-B group; (3) DAOI-C group; (4) placebo group. The study period is 24 weeks. The investigators hypothesize that DAOI may yield better efficacy than placebo for cognitive function in patients with AD.

NCT ID: NCT03752294 Not yet recruiting - Clinical trials for Mild Cognitive Impairment

A Novel Therapeutic Target for Alzheimer's Disease in Men and Women 50-85 Years of Age.

Start date: November 2018
Phase: Phase 1
Study type: Interventional

A randomized-control, double-blind, multi-center, delayed-start, pilot trial evaluating the disease modifying effects of a 150mg once-a-day dose vs. placebo of dabigatran in men and women, between the ages of 50-85 years, confirmed with MCI probably due to AD and mild Alzheimer's Disease.

NCT ID: NCT03748706 Recruiting - Alzheimer Disease Clinical Trials

Open-label, PK and Safety Study in Mild-to-moderate Alzheimer's Disease Patients

Start date: November 2018
Phase: Phase 2
Study type: Interventional

This is a Phase 2a, multi-center, open-label study of PTI-125 in mild-to-moderate AD patients, 50-85 years of age. A total of twelve (12) patients will be enrolled into the study. Patients will receive 100 mg b.i.d. of PTI-125. The objectives of this study are to investigate the safety, pharmacokinetics and effect on biomarkers of PTI-125 following 28-day repeat-dose oral administration.

NCT ID: NCT03748303 Not yet recruiting - Alzheimer Dementia Clinical Trials

Allopregnanolone Regenerative Therapeutic for Early Alzheimer's Disease: Intramuscular Study

Allo-IM
Start date: December 2018
Phase: Phase 1
Study type: Interventional

The purpose of this study is to identifying the intramuscular dose equivalent to the 4mg intravenous dose and assess its safety and tolerability as a weekly injection.

NCT ID: NCT03744312 Recruiting - Alzheimer Disease Clinical Trials

Imaging Inflammation in Alzheimer's Disease With 11C-ER176

Start date: September 10, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This study is being done to learn about inflammation in the brain of those with Alzheimer's disease (AD). The purpose of this study is to determine if 11C-ER176 is able to accurately measure inflammation in patients with Alzheimer's disease. Both patients (with either mild cognitive impairment (MCI) or Alzheimer's disease) and healthy controls (participants without memory complaints or impairment) will be included in this study.